The U.S. therapeutic plasma exchange market is consolidated and highly competitive, with the top five players accounting for ~85% of the market share in 2015. A majority of the leading players in this market are based in developed countries across North America and Europe.
Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), and Terumo BCT, Inc. (U.S.) are the leading players in this consolidated market. The leading position of Haemonetics Corporation is attributed to its wide product portfolio in both TPE devices and disposables segments. Moreover, the company has a wide geographic presence across the U.S., Europe, and Asia, which enables it to cater to customers across the globe. Around 50% of the company’s revenue is generated from the U.S. market. The company mainly focuses on acquisitions and partnerships & collaborations to maintain its leadership position in the market.
Fresenius Medical Care is another leading company in the U.S. therapeutic plasma exchange market. This is attributed to the company’s strong presence across North America, Europe, Asia-Pacific, Latin America, and Africa. The company is also expanding its presence in the emerging markets. In order to increase its market share and revenue, the company pursues the strategy of mergers and acquisitions.
In the past three years, a majority of the top players adopted agreements, collaborations, and partnerships; geographic expansions; mergers and acquisitions; and new product launches as their key growth strategies. Agreements, collaborations, and partnerships was the majorly adopted strategy by key players in the U.S. therapeutic plasma exchange market. For instance, in May 2014, Terumo BCT collaborated with Kaneka Corporation (Japan), a life sciences company, for gaining market authorization for its Terumo BCT Spectra Optia Apheresis System with Kaneka’s Liposorber LA-40S LDL Adsorption Column in the U.S.